Evidence map›Paper›PMID 38611856›Full record

ArticleMolecules (Basel, Switzerland)2024

An Approach for Engineering Peptides for Competitive Inhibition of the SARS-COV-2 Spike Protein.

Ana Paula de Abreu, Frederico Chaves Carvalho, Diego Mariano, Luana Luiza Bastos, Juliana Rodrigues Pereira Silva, Leandro Morais de Oliveira, Raquel C de Melo-Minardi, Adriano de Paula Sabino

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ana Paula de AbreuLaboratory of Bioinformatics and Systems, Department of Computer Science, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0002-1964-9323
Frederico Chaves CarvalhoLaboratory of Bioinformatics and Systems, Department of Computer Science, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0002-6592-0022
Diego MarianoLaboratory of Bioinformatics and Systems, Department of Computer Science, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0002-5899-2052
Luana Luiza BastosLaboratory of Bioinformatics and Systems, Department of Computer Science, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0002-6932-0438
Juliana Rodrigues Pereira SilvaDepartment of Biochemistry and Immunology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0009-0008-8793-9606
Leandro Morais de OliveiraLaboratory of Bioinformatics and Systems, Department of Computer Science, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0009-0006-9748-4049
Raquel C de Melo-MinardiLaboratory of Bioinformatics and Systems, Department of Computer Science, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0001-5190-100X
Adriano de Paula SabinoLaboratory of Clinical and Experimental Hematology, Clinical and Toxicological Analysis Department, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.ORCID 0000-0001-8562-8689
Universidade Federal de Minas Gerais · BR

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior 88887.503093/2020-00.
6 · The paper itself

Abstract

SARS-CoV-2 is the virus responsible for a respiratory disease called COVID-19 that devastated global public health. Since 2020, there has been an intense effort by the scientific community to develop safe and effective prophylactic and therapeutic agents against this disease. In this context, peptides have emerged as an alternative for inhibiting the causative agent. However, designing peptides that bind efficiently is still an open challenge. Here, we show an algorithm for peptide engineering. Our strategy consists of starting with a peptide whose structure is similar to the interaction region of the human ACE2 protein with the SPIKE protein, which is important for SARS-COV-2 infection. Our methodology is based on a genetic algorithm performing systematic steps of random mutation, protein-peptide docking (using the PyRosetta library) and selecting the best-optimized peptides based on the contacts made at the peptide-protein interface. We performed three case studies to evaluate the tool parameters and compared our results with proposals presented in the literature. Additionally, we performed molecular dynamics (MD) simulations (three systems, 200 ns each) to probe whether our suggested peptides could interact with the spike protein. Our results suggest that our methodology could be a good strategy for designing peptides.

Indexed as

COVID-19Spike Glycoprotein, CoronavirusHumansPeptidesSARS-CoV-2PeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19dockingmolecular dynamics simulationspeptidesPOTTERprotein–peptide interactionsSARS-CoV-2

Identifiers

PMID38611856
PMCPMC11013848
OpenAlexW4393387663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.